Summary & Overview
HCPCS J1171: Injection, Hydromorphone 0.1 mg
HCPCS Level II code J1171 denotes an injection of hydromorphone, 0.1 mg, a short‑acting opioid used for acute pain control in facility-based settings. Nationally, accurate coding for parenteral opioids matters for patient safety, opioid stewardship, billing accuracy, and oversight of controlled substance use. Clear identification of unit dosing and drug formulation supports proper reimbursement and clinical documentation.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding definitions and clinical context for J1171, typical sites of administration, payer coverage considerations, and common billing modifiers used with injectable medications. The publication also provides benchmarking guidance and policy updates relevant to opioid analgesic billing and monitoring.
This resource is intended to help billing managers, revenue cycle professionals, and clinical leaders understand the coding intent for hydromorphone injections, the contexts in which J1171 is applied, and the types of analyses and policy signals to expect when reviewing utilization and claims.
Billing Code Overview
HCPCS Level II code J1171 represents an injection of hydromorphone, 0.1 mg. This code is used to report administration of a potent short-acting opioid analgesic delivered by injection for acute pain management.
-
Service type: Injectable medication administration
-
Typical site of service: Hospital inpatient, emergency department, observation unit, ambulatory surgical center, or other facility settings where parenteral analgesia is provided
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with advanced metastatic lung cancer presents to the outpatient oncology infusion center with acute severe cancer-related pain uncontrolled by his oral opioid regimen. The clinician orders an intravenous bolus of hydromorphone for rapid analgesia. Nursing verifies allergies, recent opioid use, and respiratory status, obtains informed consent, establishes IV access, and administers the ordered dose using J1171 billed per 0.1 mg unit. The patient is observed for respiratory depression, sedation level, and pain relief for at least 30–60 minutes post-administration. Documentation includes indication, dose (converted to units of J1171), route, time, patient response, and any adverse events. Typical sites of service include outpatient infusion centers, emergency departments, hospital inpatient units, and ambulatory surgical centers when short-term parenteral opioid analgesia is required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When a portion of a single-use hydromorphone vial is discarded and the payer requires reporting of wasted medication. |